Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 2/20 | 0.63 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.63 |
| ▸ | CTSA | P10619 | 2/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.51 |
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | LIPE | Q05469 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6120802 | 0.84 | OPRM1 (0.67) | GRNSORT1CTSAGABRA5OPRM1 | |
| SCHEMBL13485797 | 0.82 | GRN (0.58) | GRNSORT1CTSAOPRM1OPRD1 | |
| SCHEMBL14226713 | 0.81 | GRN (0.57) | GRNSORT1CTSAOPRM1OPRD1 | |
| SCHEMBL6927923 | 0.81 | GABRA5 (0.63) | GRNSORT1GABRA5 | |
| SCHEMBL13701799 | 0.81 | NNMT (0.58) | GRNSORT1GABRA5HPGDSRAB9A | |
| SCHEMBL30212494 | 0.81 | GRN (0.57) | GRNSORT1CTSAOPRM1OPRD1 | |
| SCHEMBL7637674 | 0.80 | NPC1 (0.63) | GRNSORT1CTSARAB9A | |
| SCHEMBL29523613 | 0.80 | GRN (0.60) | GRNSORT1CTSAGABRA5OPRM1 | |
| SCHEMBL29035422 | 0.80 | GRN (0.60) | GRNSORT1CTSAGABRA5OPRM1 | |
| SCHEMBL3586183 | 0.80 | LMNA (0.60) | GRNSORT1CTSAGABRA5OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | GRN 4400/4885SORT1 3475/4885CTSA 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.